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Since discovering PfEMP1 virulence proteins in Plasmodium falciparum, malariologists have struggled to
reconcile their limitless sequence diversity with their binding to relatively few host receptors. In this issue
of Cell Host & Microbe, Lau et al. (2015) explore how diverse PfEMP1s embrace EPCR, promoting parasite
survival and killing African children.Even today, Plasmodium falciparum ma-
laria continues to threaten the lives of
countless African children (World Health
Organization, 2014), causing frequent
bouts of febrile illness and, in some cases,
deaths from cerebral malaria (i.e., coma,
convulsions), severe anemia, and respira-
tory distress. While the pathophysiology
of these clinical syndromes is complex
and not fully understood, one thing is
clear: the binding of parasite-infected
red blood cells (iRBCs) to microvascular
endothelial cells is the prime mediator of
disease. Without this interaction, iRBCs
would be filtered from the bloodstream
by the spleen, and all other organs would
be free of the microvascular obstruction,
inflammation, and dysfunction that pro-
duce malaria symptoms. Defining the
parasite ligand-host receptor interactions
that mediate cytoadherence is therefore
critical to improving our understanding
of malaria pathogenesis and developing
vaccines and adjunct therapies to miti-
gate disease severity.
P. falciparum parasites are inoculated
into humans by the blood-seeking female
Anopheles mosquito. After emigrating
from the skin and passing through the
liver, these parasites circulate in the
peripheral blood, where they repeatedly
invade, replicate in, and egress from
RBCs in 48 hr cycles. In the latter
24 hr of intraerythrocytic development,
P. falciparum induces dramatic alter-
ations in the shape and rigidity of its host
RBC. These changes, which are similar
to those that occur during the natural
process of RBC senescence, mark iRBCs
for efficient mechanical filtration in the
spleen. To avoid this encounter, parasite
populations express P. falciparum eryth-
rocyte membrane protein 1 (PfEMP1), a
family of antigenically variant proteins en-10 Cell Host & Microbe 17, January 14, 2015coded by var genes (Baruch et al., 1995;
Smith et al., 1995; Su et al., 1995), on
the surface of their host iRBCs. A given
parasite lineage can clonally express
about 60 PfEMP1 variants, each of which
contains 2–10 Duffy binding-like (DBL)
and cysteine-rich interdomain region
(CIDR) domains (Figure 1A).
In human microvessels, these PfEMP1
domains carry out two important func-
tions. The first is tomediate the cytoadher-
ence of iRBCs to microvascular endothe-
lial cells in virtually all of the body’s
organs. This enables parasites to avoid
the spleen altogether, complete their
development in the low oxygen tension
environment of post-capillary venules,
andmultiply to high densities in the blood-
stream, where their sexual forms are taken
up by Anopheles mosquitoes and trans-
mitted to another host. The second is to
evade specific immune responses through
antigenic variation. This involves switching
the clonal expression of PfEMP1 antigens,
enabling iRBCs to steer clear of immuno-
globulin (IgG) responses that prevent their
cytoadherence and opsonize them for
phagocytosis. PfEMP1 variants thus play
a critical role in parasite survival and are
prime targets for naturally acquired immu-
nity in African children. Recapitulating this
immunity throughPfEMP1vaccinationhas
been difficult to orchestrate, especially as
thousands of diverse PfEMP1 variants
continue to be identified through whole-
genome sequencing efforts and addi-
tional mechanisms of antigenic variation
reported (Claessens et al., 2014).
Given the primary role of PfEMP1 in
parasite survival, and the ability of the hu-
man immune system to generate exqui-
sitely specific IgG responses, it is not
surprising that P. falciparum populations
have evolved constellations of PfEMP1ª2015 Elsevier Inc.domains with almost limitless sequence
diversity. Even within subclasses of DBL
and CIDR domains, the level of sequence
diversity is impressive. Since the discov-
ery of var genes 20 years ago, malariolo-
gists have wondered how exceptionally
diverse PfEMP1 domains are able to
bind to limited numbers of host receptors.
Examples include interactions between
CIDRa2 and CIDRa3 domains with
the mammalian membrane glycoprotein
CD36 and CIDRa1 domains with the
endothelial protein C receptor (EPCR)
(Figure 1A) (Turner et al., 2013). Despite
their enormous sequence diversity,
might domains within the same subclass
share structurally conserved features
that mediate binding to a single receptor?
Since a large proportion of PfEMP1
variants have CIDRa1 domains, and their
binding to EPCR was recently implicated
in severe childhood malaria (Moxon
et al., 2013; Turner et al., 2013), in this
issue Lau et al. (2015) focused their inves-
tigation on the CIDRa1-EPCR interaction
to answer this question.
Analysis of two different CIDRa1-EPCR
crystal structures, combinedwith analysis
of 885 CIDRa1 domain sequences, re-
vealed that the region of CIDRa1 that
binds EPCR with nanomolar affinities
and slow dissociation rates is incredibly
diverse, yet conserved in both shape and
bonding potential (Figure 1A). Specifically,
three amino acids in CIDRa1 stabilize a
kinked a helix that protrudes a phenylala-
nine into the hydrophobic groove of
EPCR. This residue resides on a hydro-
phobic patch that is complementary in
shape to EPCR and surrounded by seven
amino acids that form hydrogen bonds
with EPCR side chains. While many of
these residues are found to be diversified
in other CIDRa1 domains, the changes
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Figure 1. The Magic of High-Affinity CIDRa1-EPCR Interactions Unveiled
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is a family of multi-domain, antigeni-
cally variant, clonally expressed proteins on the surface of parasite-infected red blood cells (iRBCs).
PfEMP1 proteins are comprised of 2–10 DBL and CIDR domains, each of which has an identified or pu-
tative host receptor. CIDRa1 domains were recently shown to bind endothelial protein C receptor
(EPCR) and mediate the binding of iRBCs to microvascular endothelial cells, an important step in malaria
pathogenesis.
(A) Two PfEMP1 proteins with highly diverse CIDRa1 domains (light and dark blue) that present a similar
EPCR-binding surface, comprised of a hydrophobic patch (dark gray) that protrudes a phenylalanine (F)
into the EPCR hydrophobic groove, and multiple surrounding residues (light gray) that form hydrogen
bonds with EPCR side chains.
(B) CIDRa1.1 peptide-specific antibodies (red) that were purified from Tanzanian children and shown
to block the binding of a heterologous CIDRa1.4 domain to EPCR. Such antibodies, whether naturally ac-
quired or vaccine induced, may mitigate the severity of malaria not only by preventing the cytoadherence
of iRBCs, but also restoring the binding of activated protein C (APC) to EPCR—an interaction with antico-
agulant and cytoprotective effects in microvessels.
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hydrophobicity and hydrogen-bonding
potential are maintained. All 14 totally
conserved residues were found in the
CIDRa1 domain core, where mostly aro-
matics facilitate helical packing andcyste-
ines form disulfide bonds to stabilize the
EPCR-binding surface. Remarkably, acti-
vated protein C (APC), the natural ligand
of EPCR, also protrudes a phenylalanine
into the hydrophobic groove of EPCR,
suggesting that P. falciparum has evolved
to bind a functional and sequence-con-
strainedportion of this receptor. Together,
these findings suggest that P. falciparum
populations have evolved high-affinity
CIDRa1-EPCR interactions that are not
easily broken by human antibody re-
sponses specific for CIDRa1 or genetic
polymorphism in EPCR.
This landmark study also has substan-
tial implications for the rational develop-ment of PfEMP1-based vaccines. Clearly,
a vaccine that effectively breaks up natu-
rally occurring CIDRa1-EPCR interactions
in African children will need to elicit an
antibody repertoire that recognizes a
diverse array of CIDRa1 domains. A single
recombinant CIDRa1 domain may not be
an adequate immunogen for such a vac-
cine, unless it induces a broadly neutral-
izing antibody response—a possibility
that Lau et al. (2015) have begun to
explore. Using peptides from the EPCR-
binding region of two different CIDRa1
domains, these investigators affinity puri-
fied antibodies from Tanzanian children
and showed that they partially block the
binding of heterologous CIDRa1 domains
and CIDRa1-expressing iRBCs to EPCR
(Figure 1B). While a cocktail vaccine of
several CIDRa1 peptides might induce
a similar domain-transcending antibody
response, another approach to achieveCell Host & Microbe 1this might be to synthesize a novel pep-
tide that mimics the conserved shape
and bonding potential of diverse CIDRa1
domains. Even if such peptide-based
vaccines succeed in only weakening
PfEMP1’s tight embrace of EPCR, this
may sufficiently reduce the incidence
and severity of malaria in African children.
Indeed, this type of partial protection is
conferred by sickle cell trait and other
RBC polymorphisms that weaken cytoad-
herence interactions through a mecha-
nism of abnormal PfEMP1 display (Fair-
hurst et al., 2012).
The findings of Lau et al. (2015) pave
new roads for basic scientific and clinical
investigations. Many questions about
the pathophysiologic processes occurring
at the iRBC-endothelial cell interface,
and the immune and genetic resistance
mechanisms that antagonize them, remain
unanswered. For example, when CIDRa1-
EPCR interactions are specifically tar-
geted by antibodies, can other non-tar-
geted interactions, such as those between
multipleDBLdomains in thesamePfEMP1
molecule and their putative receptors
on the same endothelial cell (Figure 1),
mediate some degree of iRBC cytoadher-
ence? Are the CD36-binding regions of
diverse CIDRa2 and CIDRa3 domains
also conserved in both shape and bonding
potential and thus targets for rational vac-
cine development as well? Do sickle cell
and hemoglobin C traits confer substan-
tial protection from cerebral malaria by
impeding CIDRa1-EPCR interactions and
mitigating their detrimental effects in the
brain? The recent discovery of EPCR as a
receptor for PfEMP1, and these latest find-
ingsofLauetal. (2015), lay thegroundwork
for answering these and related questions
in an effort to render malaria a non-lethal
disease in Africa.
In summary, Lau et al. (2015) have
significantly advanced our understanding
of malaria pathogenesis and immunity in a
way that will undoubtedly re-energize ef-
forts to produce PfEMP1-based vaccines
for severe childhood malaria. Importantly,
they also provide yet another example
of how international collaborations are
highly effective in making impactful dis-
coveries (Adams, 2013).ACKNOWLEDGMENTS
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